Dr. Costa on Unmet Needs in Relapsed/Refractory Multiple Myeloma

Partner | Cancer Centers | <b>O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham</b>

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma. 

Luciano J. Costa, MD, PhD, an associate professor of medicine in the Blood and Marrow Transplantation and Cell Therapy Program at the University of Alabama's Birmingham School of Medicine, discusses unmet need​s in relapsed/refractory multiple myeloma. 

Despite recent advancements in the multiple myeloma space, several challenges need to be addressed, says Costa. 

Some patients progress after proteasome inhibitors, immunomodulatory drugs​, and monoclonal antibodies​, Costa explains. Moreover, there are limited options that can support patients in these ​scenario​s.

A majority of available or emerging therapies produce low response rate​s of around 30%. ​As such, developing more effective and safer regimens remains an unmet need in this setting, Costa concludes.